{"brief_title": "Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1", "brief_summary": "The purpose of this study is to determine whether terlipressin is safe and effective in the treatment of patients with hepatorenal syndrome (HRS) type 1 when compared to placebo.", "condition": ["Hepatorenal Syndrome"], "intervention_type": ["Drug"], "intervention_name": ["terlipressin"], "arm_group_label": ["Terlipressin"], "criteria": "Inclusion Criteria: - Chronic, or acute liver disease - Rapidly progressive reduction in renal function, e.g. doubling of serum creatinine to >2.5 mg/dL in less than two weeks. - No sustained improvement in renal function after diuretic withdrawal and plasma volume expansion - Proteinuria <500 mg per day - No evidence of granular casts in urinalysis or ultrasonographic evidence of obstructive uropathy or parenchymal renal disease Exclusion Criteria: - Ongoing shock - Uncontrolled bacterial infection - Current significant fluid losses - Current or recent treatment with nephrotoxic drugs (e.g. NSAIDs or aminoglycosides within 4 weeks) - Acute liver disease due to factors known to be also directly nephrotoxic (e.g. acetaminophen overdose) - Confirmed pregnancy - Severe cardiovascular disease - Evidence of intrinsic or parenchymal renal disease (e.g. acute tubular necrosis) - Participation in other clinical studies within 30 days", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "terlipressin", "mesh_term": ["Syndrome", "Hepatorenal Syndrome", "Terlipressin", "Lypressin"], "id": "NCT00089570"}